TECNOTREE
1.8.2024 15:30:28 CEST | Business Wire | Press release
Tecnotree, a global digital platform and services leader for BSS, OSS, AI, 5G, and cloud-native technologies, has partnered with MiFibra, a leading High-Speed Broadband Internet Service Provider in Perú, to update its Operations Support Systems and transform Fulfillment and Assurance processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801164212/en/
Tecnotree and MiFibra Collaborate to Revolutionize its Operations Support Systems (Graphic: Business Wire)
The strategic partnership will allow MiFibra to fully realize the potential of its Fiber to the Home (FTTH) network infrastructure, offering several benefits, such as the capability to automate feasibility, provisioning and maintenance of services, removing complexities and delays related to manual tasks, as well offering the capability to guarantee the quality of services (QoS) and the quality of the experience (QoE). The results of this partnership will allow MiFibra to accelerate the growth of its customer base, increase customer satisfaction and strengthen its position in the market.
It will also expose TMForum's open APIs for service qualification and activation, enabling seamless integration and compatibility with a variety of protocols and network elements. MiFibra will be able to fully optimize the capacity and usage of its network infrastructure, and, through efficient resources management, it will be able to achieve operational excellence.
Carlos Villegas, CEO of MiFibra, said: "The partnership between MiFibra and Tecnotree represents a transformative step towards comprehensive provisioning with greater and better information for commercial and technical customer management. Through this strategic alliance, MiFibra will be able to evolve its commercial and technical service platforms over time by incorporating digital self-management tools for the customer, a proactive communication portal for the customer, and tools for optimizing home equipment."
Padma Ravichander, CEO of Tecnotree Corporation, said, “We are delighted with this new partnership with MiFibra to embark on a transformative journey towards digitalization and operational efficiency, by revolutionizing their infrastructure and operational support systems. By leveraging our expertise in BSS, OSS, Artificial Intelligence and 5G technologies, Tecnotree will enable MiFibra to unlock its true potential and drive growth by provisioning services quicker and assurance of quality of its services. Through increased automation and streamlined processes, we will enable fast and agile interactions at scale, which will not only fuel MiFibra's customer base, but will also fortify their market position.”
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) & Operating Support System (OSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is No. 1 on the TM Forum Open API Conformance table with 59 Open APIs, a result of our pursuit of delivering excellence, and consistently providing differentiated experiences and services to the CSPs and DSPs. Our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
About MiFibra
MiFibra is a company founded by Peruvian executives with over 20 years of experience in the telecommunications sector. It currently has broadband fiber optic networks in the departments of Piura, Lambayeque, Trujillo, and Ancash, with coverage of more than 800,000 households and over 80,000 connected customers. It has been recognized by Ookla as the leading Fixed Internet operator in terms of speed in all the departments where it operates. Its mission is to bring world-class internet service to more and more Peruvians, and its vision is to become the number one operator wherever it operates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801164212/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom